financetom
Business
financetom
/
Business
/
Stellantis H1 Adjusted Earnings, Revenue Decrease; Updates 2025 Tariff Impact Estimate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis H1 Adjusted Earnings, Revenue Decrease; Updates 2025 Tariff Impact Estimate
Jul 29, 2025 1:32 AM

04:07 AM EDT, 07/29/2025 (MT Newswires) -- Stellantis ( STLA ) reported H1 adjusted earnings Tuesday of 0.18 euro ($0.21) per diluted share, down from 2.36 euros a year earlier.

Analysts polled by FactSet expected 0.50 euro.

Net revenue for the period ended June 30 was 74.26 billion euros, down from 85.02 billion euros a year earlier.

Analysts polled by FactSet expected 74.08 billion euros.

The company re-established its financial guidance and said it expects H2 revenue to increase sequentially from H1. Stellantis ( STLA ) also updated its 2025 net tariff impact estimate to about 1.5 billion euros, out of which 300 million euros was incurred in H1, it said.

The company's shares were down 3.4% in premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Ultragenyx Completes Patient Enrollment in Angelman Syndrome Phase 3 Trial
Ultragenyx Completes Patient Enrollment in Angelman Syndrome Phase 3 Trial
Aug 1, 2025
05:11 AM EDT, 08/01/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said late Thursday it completed patient enrollment in a phase 3 trial of GTX-102 for the treatment of Angelman syndrome, a neurogenetic disorder. The trial, which enrolled 129 subjects, is expected to be completed in H2 2026. The company said it expects to start a separate study of...
Newmont Sells Entire Stake in Orosur Mining
Newmont Sells Entire Stake in Orosur Mining
Aug 1, 2025
05:07 AM EDT, 08/01/2025 (MT Newswires) -- Newmont ( NEM ) said late Thursday it sold its 29.2 million shares of Orosur Mining in a private deal at 0.19 Canadian dollar ($0.14) per share for gross proceeds of CA$5.5 million. The company said it held a 9.4% stake in Orosur Mining before the sale. Following the transaction, it no longer...
Arena Group Approves 3 Million Share Buyback Program
Arena Group Approves 3 Million Share Buyback Program
Aug 1, 2025
05:04 AM EDT, 08/01/2025 (MT Newswires) -- Arena Group ( AREN ) said late Thursday its board authorized a 3 million-share repurchase program. The company may buy back the shares over the next 12 months. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved